Axhidrox: Uses, Dosage & Side Effects
A topical anticholinergic cream for the treatment of severe primary axillary hyperhidrosis (excessive underarm sweating) in adults
Axhidrox is a prescription topical cream containing glycopyrronium (as glycopyrronium bromide), an anticholinergic agent that reduces sweat production by blocking the action of acetylcholine on eccrine sweat glands. It is specifically indicated for the treatment of severe primary axillary hyperhidrosis in adults — a condition characterized by excessive, unprovoked sweating in both underarms that typically occurs during the day but not during sleep. Axhidrox is applied directly to the armpits using the pump cap as an applicator, daily for the first four weeks and then twice weekly from week five onwards. Clinical studies have demonstrated significant reductions in sweat production, with a favorable safety profile primarily involving anticholinergic-related effects such as dry mouth.
Quick Facts: Axhidrox
Key Takeaways
- Axhidrox contains glycopyrronium bromide, an anticholinergic agent applied topically to the armpits that blocks the nerve signals triggering eccrine sweat gland activity, leading to a clinically significant reduction in underarm sweating.
- The cream is applied once daily for the first 4 weeks (preferably in the evening) using the pump cap as an applicator — never with fingers — and from week 5 onwards the frequency can be reduced to twice weekly based on treatment response.
- The most common side effect is dry mouth (affecting more than 1 in 10 users), reflecting the systemic anticholinergic effect; other common effects include local skin irritation, dry nasal mucosa, dry eyes, and constipation.
- Axhidrox is contraindicated in patients with narrow-angle glaucoma, myasthenia gravis, Sjögren’s syndrome, severe ulcerative colitis, and certain cardiovascular conditions with hemodynamic instability.
- Each 50 g multi-dose container with pump delivers 124 actuations (enough for 31 treatments), and should not be used beyond 12 months after first opening — no special storage conditions are required.
What Is Axhidrox and What Is It Used For?
Axhidrox contains the active substance glycopyrronium (administered as glycopyrronium bromide), a quaternary ammonium compound that acts as a muscarinic receptor antagonist. Glycopyrronium has been used in medicine for decades, primarily in oral and injectable forms as a pre-anesthetic agent to reduce salivary and bronchial secretions and in the management of peptic ulcer disease. However, in Axhidrox, it has been formulated as a topical cream specifically designed for direct application to the skin of the underarms, allowing it to target the eccrine sweat glands responsible for axillary sweating.
Primary axillary hyperhidrosis is a chronic condition characterized by excessive sweating in both underarms without an identifiable external cause. Unlike secondary hyperhidrosis, which is triggered by underlying medical conditions (such as thyroid disorders, diabetes, or infections), medications, or hormonal changes, primary hyperhidrosis has no clear medical explanation. The condition is believed to result from overactivity of the sympathetic nervous system, which sends exaggerated nerve signals to the eccrine sweat glands. A hallmark feature of primary axillary hyperhidrosis is that the excessive sweating typically occurs during the day but generally does not happen during sleep, distinguishing it from sweating caused by systemic illness.
The mechanism of action of Axhidrox is straightforward but highly targeted. Sweating is controlled by the sympathetic nervous system, which releases the neurotransmitter acetylcholine at the junction between nerve endings and eccrine sweat glands. Acetylcholine binds to muscarinic receptors (primarily the M3 subtype) on the surface of sweat gland cells, triggering the production and secretion of sweat. Glycopyrronium competitively blocks these muscarinic receptors, preventing acetylcholine from activating the sweat glands. When applied topically to the axillary skin, glycopyrronium penetrates to the level of the sweat glands and inhibits their activity, resulting in a measurable reduction in sweat output at the treated area.
The condition affects an estimated 1–5% of the global population, with primary axillary hyperhidrosis being one of the most common presentations. The impact on quality of life can be substantial: patients frequently report embarrassment, social anxiety, difficulty with daily activities, damage to clothing, and interference with professional and intimate relationships. Despite its prevalence, hyperhidrosis is significantly underdiagnosed and undertreated, with many patients suffering in silence for years before seeking medical help. Axhidrox provides a targeted topical treatment option that addresses the condition directly at its source, offering patients a practical alternative to systemic anticholinergic medications (which can cause widespread side effects), botulinum toxin injections (which require clinic visits and repeated procedures), and surgical interventions (which carry risks of compensatory sweating).
Clinical trials evaluating Axhidrox in patients with severe primary axillary hyperhidrosis have demonstrated statistically significant and clinically meaningful reductions in gravimetric sweat production (measured by weight of sweat absorbed on filter paper) compared with vehicle cream (placebo). Patients treated with Axhidrox also reported improvements in their Hyperhidrosis Disease Severity Scale (HDSS) scores, a validated patient-reported outcome measure that assesses how much sweating interferes with daily activities. The onset of action is generally observed within the first few weeks of daily application, with continued improvement as treatment progresses.
Axhidrox is indicated only for primary axillary hyperhidrosis — excessive sweating without an identifiable medical cause. If your excessive sweating is due to medications, thyroid conditions, menopause, infections, or other medical conditions, it is classified as secondary hyperhidrosis and requires treatment of the underlying cause. Key features of primary hyperhidrosis include bilateral and relatively symmetric sweating, onset before age 25, occurrence at least once per week, absence during sleep, and often a family history of the condition. Your doctor will assess whether your sweating is primary or secondary before prescribing Axhidrox.
What Should You Know Before Using Axhidrox?
Contraindications
Axhidrox must not be used in certain medical situations where the anticholinergic effects of glycopyrronium could worsen existing conditions or create dangerous complications. The following are absolute contraindications to Axhidrox use:
- Allergy to glycopyrronium or excipients: Do not use Axhidrox if you are allergic to glycopyrronium bromide or to any of the other ingredients in the formulation, including benzyl alcohol, propylene glycol, or cetostearyl alcohol. Allergic reactions can range from local skin irritation to severe systemic anaphylaxis.
- Narrow-angle glaucoma: Anticholinergic agents can increase intraocular pressure by causing pupil dilation (mydriasis), which can precipitate an acute angle-closure crisis in patients with narrow-angle glaucoma. This is a medical emergency that can lead to permanent vision loss if not treated promptly.
- Acute hemorrhage with unstable cardiovascular status: In patients with acute bleeding accompanied by hemodynamic instability (low blood pressure, rapid heart rate), the anticholinergic effects on heart rate could mask important clinical signs and worsen the cardiovascular situation.
- Severe ulcerative colitis: Anticholinergic agents reduce intestinal motility, which could worsen colonic dilation and delay the recognition of serious complications in patients with active severe ulcerative colitis.
- Toxic megacolon complicating ulcerative colitis: This life-threatening complication of inflammatory bowel disease involves extreme colonic dilation. Anticholinergic drugs further reduce gut motility and can accelerate progression of this condition.
- Myasthenia gravis: This autoimmune neuromuscular disease involves impaired acetylcholine signaling at the neuromuscular junction. Blocking muscarinic receptors with an anticholinergic agent could theoretically worsen some aspects of autonomic dysfunction in these patients.
- Sjögren’s syndrome: This autoimmune condition causes chronic dryness of the eyes and mouth due to destruction of salivary and lacrimal glands. Adding an anticholinergic medication could severely worsen these already debilitating symptoms.
Warnings and Precautions
Stop using Axhidrox and consult your doctor immediately if you notice symptoms of urinary retention, such as a weak urine stream, dribbling, increased need to urinate, or a feeling that your bladder is full or not completely emptied. Anticholinergic agents can impair bladder muscle function, and urinary retention requires prompt medical attention.
Before starting treatment with Axhidrox, discuss the following important precautions with your doctor:
- Application site only: Axhidrox must only be applied to the skin in the armpits. Do not apply the cream to any other body part. Avoid contact with the eyes, nose, and mouth. If accidental contact occurs, immediately rinse the affected area with plenty of water to minimize the risk of local anticholinergic effects such as blurred vision (eyes), nasal dryness (nose), or dry mouth (mouth).
- Prevent transfer to others: Cover the treated armpits with clothing during intimate contact, as anticholinergic effects cannot be excluded if other people come into contact with the cream on your skin.
- Dental care: If you experience dry mouth as a side effect, brush your teeth carefully and visit your dentist regularly, as reduced saliva flow increases the risk of dental caries (tooth decay), gum disease, and oral infections.
- Overheating risk: Do not apply Axhidrox to body parts other than the armpits (such as palms, feet, or face) or to large areas of the body. Significant reduction of sweating over large body surface areas can impair the body’s ability to regulate its temperature through evaporative cooling, potentially leading to overheating and, in extreme cases, life-threatening heat stroke.
Children and Adolescents
Axhidrox is not recommended for use in children and adolescents under 18 years of age. The safety and efficacy of glycopyrronium cream have not been established in this younger age group, and there are currently no clinical data to support its use in pediatric patients. Hyperhidrosis in children and adolescents may require different treatment approaches, and a dermatologist experienced in managing hyperhidrosis in younger patients should be consulted.
Pregnancy and Breastfeeding
If you are pregnant, think you may be pregnant, or are planning to become pregnant, consult your doctor before using Axhidrox. There are no adequate clinical data on the use of Axhidrox in pregnant women, and it is not known whether glycopyrronium from topical application can reach the developing fetus in clinically relevant amounts. Your doctor will discuss whether the benefit of treating your hyperhidrosis outweighs any potential risk during pregnancy.
It is not known whether glycopyrronium is excreted in human breast milk following topical application. If you are breastfeeding, you and your doctor must decide whether to stop breastfeeding or to discontinue Axhidrox treatment, taking into account the benefit of breastfeeding for your child and the benefit of treatment for you. The primary concern is to ensure that your infant does not come into direct contact with the cream or the treated skin.
Driving and Operating Machinery
Blurred vision, drowsiness, fatigue, and dizziness can occur after using Axhidrox. Blurred vision is particularly likely if the cream accidentally comes into contact with the eyes. Do not drive, operate machinery, or perform hazardous activities until these effects have resolved. You are personally responsible for assessing whether you are fit to drive or perform work that requires alertness. Use of medications is one of the factors that can affect your ability in these respects — read all the information in this article for guidance and discuss with your doctor or pharmacist if you are uncertain.
Important Information About Ingredients
Axhidrox contains several excipients that may cause reactions in sensitive individuals:
- Benzyl alcohol (E1519): Each pump actuation contains approximately 2.7 mg of benzyl alcohol, which may cause allergic reactions and mild local irritation in some people.
- Propylene glycol (E1520): Each pump actuation contains approximately 8.1 mg of propylene glycol, a common pharmaceutical excipient that is generally well tolerated but can cause skin irritation in sensitive individuals.
- Cetostearyl alcohol: This fatty alcohol can cause local skin reactions such as contact dermatitis (eczema) in people with a sensitivity to this ingredient.
How Does Axhidrox Interact with Other Drugs?
While Axhidrox is a topical medication applied only to the armpits, some glycopyrronium is absorbed systemically through the skin. Although systemic levels are generally low compared to oral or injectable administration, they can be sufficient to produce systemic anticholinergic effects, as evidenced by the occurrence of dry mouth in more than 10% of users. This systemic absorption means that Axhidrox can interact with other medications that have anticholinergic properties, potentially amplifying side effects.
The following drug interactions are clinically relevant and should be discussed with your doctor before starting Axhidrox:
| Drug Category | Examples | Risk |
|---|---|---|
| Topiramate | Used for epilepsy and migraine prevention | Increased anticholinergic effects; risk of overheating due to reduced sweating |
| Sedating antihistamines | Diphenhydramine, hydroxyzine, chlorphenamine, promethazine | Increased dry mouth, drowsiness, constipation, urinary retention |
| Tricyclic antidepressants | Amitriptyline, nortriptyline, clomipramine, imipramine | Significantly increased anticholinergic burden; dry mouth, constipation, blurred vision |
| MAO inhibitors | Moclobemide, selegiline, rasagiline | Enhanced anticholinergic effects; used for depression or Parkinson’s disease |
| Antipsychotics / Neuroleptics | Chlorpromazine, quetiapine, olanzapine, clozapine | Additive anticholinergic effects; increased risk of constipation, dry mouth, confusion |
| Opioids | Codeine, tramadol, morphine, oxycodone | Increased constipation, urinary retention, drowsiness |
The concept of “anticholinergic burden” is important to understand when considering Axhidrox in the context of your overall medication regimen. Many commonly used medications have varying degrees of anticholinergic activity, and their effects are cumulative. When multiple anticholinergic drugs are used together, the risk and severity of anticholinergic side effects — including dry mouth, constipation, urinary retention, blurred vision, cognitive impairment, and increased heart rate — can increase significantly. This is particularly relevant for older adults, who are more sensitive to anticholinergic effects.
Always inform your doctor, pharmacist, or other healthcare professional about all medications you are currently taking, have recently taken, or might take. This includes prescription medications, over-the-counter drugs, herbal supplements, and any other topical treatments you apply to your skin. Your doctor can assess the total anticholinergic burden of your medications and determine whether Axhidrox is appropriate for you, or whether dose adjustments of other medications may be necessary.
If you are already taking a medication with anticholinergic properties and your doctor prescribes Axhidrox, be vigilant for increased side effects such as worsening dry mouth, difficulty urinating, constipation, or blurred vision. Report any new or worsening symptoms to your doctor promptly. In many cases, the interaction can be managed with monitoring and symptomatic treatment, but in some situations your doctor may need to adjust your medication regimen.
What Is the Correct Dosage of Axhidrox?
Always use Axhidrox exactly as your doctor has instructed. If you are unsure, check with your doctor or pharmacist. The medication is for external use only and should only be applied to the skin of the armpits.
Adults
| Treatment Phase | Dose per Armpit | Frequency | Timing |
|---|---|---|---|
| Weeks 1–4 (Induction) | 2 pump actuations | Once daily | Preferably in the evening |
| Week 5 onwards (Maintenance) | 2 pump actuations | Twice weekly | As needed, based on response |
The recommended dose is two pump actuations per armpit. Each treatment (both armpits) therefore requires four pump actuations in total. During the first four weeks of treatment (the induction phase), apply Axhidrox evenly in each armpit once daily, preferably in the evening. This daily application allows glycopyrronium to build up a consistent effect on the sweat glands. From week five onwards, you may reduce the application frequency to twice per week, depending on how much your sweat production has decreased. Your doctor will advise you on the appropriate maintenance frequency based on your individual response.
How to Apply Axhidrox
Priming the pump (first use only): Before using Axhidrox for the first time, you must remove the trapped air from the pump mechanism. Pull off the pump cap. Place a piece of paper on a table. Angle the pump and press down several times until cream starts to come out of the opening. Then slowly press the pump down fully an additional 10 times, letting the dispensed cream fall onto the paper. Dispose of the paper with the dispensed cream as household waste. The pump is now ready to use and does not need to be primed again.
Application with the pump cap:
- Pull off the pump cap.
- Hold the pump in your hand with the opening pointing toward the removed cap.
- Press the pump down fully two times to dispense the recommended amount of cream onto the top of the cap.
- Spread the cream evenly in one armpit using the cap as an applicator.
- Repeat the procedure for the other armpit (two more pump actuations onto the cap).
- After application, wash the pump cap and immediately wash your hands thoroughly with soap and water. This is critical to prevent the cream from coming into contact with your nose, eyes, or mouth.
- Mark the number of treatments in the table on the outer carton. One treatment equals 4 pump actuations (2 per armpit).
Children and Adolescents
Axhidrox is not recommended for patients under 18 years of age. The safety and efficacy have not been established in this age group, and no dosing recommendations can be made for pediatric patients.
Missed Dose
If you forget to apply Axhidrox, simply skip the missed application and apply the next dose at the usual time. Do not apply a double amount to make up for a forgotten dose. Consistent application is important for optimal results, but a single missed dose is unlikely to significantly impact overall treatment effectiveness.
Overdose
Overdose is unlikely if you only apply Axhidrox to the armpits as directed. However, applying the cream too frequently, in excessive amounts, or to other body areas (palms, feet, face) or large skin surfaces can increase the risk and severity of anticholinergic side effects. A significant reduction in sweating over large body areas can impair temperature regulation, potentially leading to dangerous overheating and life-threatening heat stroke. Stop using Axhidrox immediately and seek urgent medical attention if you experience an increased sensation of warmth or elevated body temperature.
If you have used too much Axhidrox, or if a child has accidentally come into contact with or ingested the medication, seek medical advice immediately. Contact your local poison control center or emergency services for risk assessment and guidance.
Stopping Treatment
If you or your doctor decide to stop using Axhidrox, be aware that excessive underarm sweating will return once treatment is discontinued. Axhidrox provides symptomatic relief for as long as it is used but does not cure the underlying condition. If you have questions about stopping or continuing treatment, discuss them with your doctor.
What Are the Side Effects of Axhidrox?
Like all medicines, Axhidrox can cause side effects, although not everyone who uses it will experience them. The side effects of Axhidrox are primarily related to its anticholinergic mechanism of action: by blocking muscarinic receptors to reduce sweating, glycopyrronium can also affect other muscarinic receptor-mediated functions throughout the body, including saliva production, tear production, intestinal motility, bladder function, and pupil size. The extent to which these systemic effects occur depends on how much glycopyrronium is absorbed through the skin and enters the bloodstream.
Clinical trials and post-marketing surveillance have identified the following side effects, categorized by frequency of occurrence:
Stop using Axhidrox and contact your doctor or nearest emergency department immediately if you experience swelling of the face, lips, or throat (which may make it difficult to swallow or breathe), itching, and rash. These may be signs of a serious allergic reaction or angioedema (frequency not known) that may require emergency medical treatment. Also seek immediate medical care if you experience sudden blurred vision (uncommon side effect).
Very Common
May affect more than 1 in 10 people
- Dry mouth (xerostomia)
Common
May affect up to 1 in 10 people
- Irritation at the application site
- Pain at the application site
- Itching at the application site
- Inflamed hair follicle at the application site
- Dry nasal mucosa
- Dry eyes
- Dry skin
- Headache
- Constipation
Uncommon
May affect up to 1 in 100 people
- Local effects: dryness, acne, swelling, skin hardening, scarring, small blisters, sores, pustules, folliculitis at application site
- Skin: eczema, generalized itching, rash, skin redness, atopic dermatitis, skin irritation, skin plaques, acne, urticaria (hives), abnormal body odor, parapsoriasis
- Dryness: dry lips, dry hands, dry mucous membranes, dry throat, absence of saliva
- Eyes: itchy, red or irritated eyes, unequal pupil sizes, dilated pupils, blurred vision, visual impairment
- Gastrointestinal: abdominal distension, hard stools, indigestion, nausea, mouth and throat pain
- Nervous system: drowsiness, fatigue, attention disturbance, restlessness, anxiety, insomnia or poor sleep quality, dizziness, head discomfort
- Other: nasal congestion, throat tightness, impaired bladder emptying, excessive sweating (paradoxical), decreased platelet count, rapid heart rate (tachycardia), prolonged QT interval on ECG, elevated liver enzymes, elevated bilirubin, increased red blood cell volume, decreased hemoglobin concentration
Not Known
Frequency cannot be estimated from available data
- Angioedema (swelling of the face, lips, or throat)
- Severe allergic reaction (anaphylaxis)
Dry mouth is the most frequently reported side effect of Axhidrox, reflecting the systemic absorption of glycopyrronium and its effect on salivary gland muscarinic receptors. While usually mild to moderate, persistent dry mouth can increase the risk of dental problems including tooth decay, gum disease, and oral thrush. If you experience dry mouth, maintain excellent oral hygiene by brushing your teeth at least twice daily with fluoride toothpaste, drinking water regularly, and visiting your dentist for regular check-ups.
Local application site reactions such as irritation, pain, and itching are also commonly reported. These are generally mild and tend to improve as the skin adapts to the treatment. If local reactions are bothersome or do not improve, consult your doctor about whether to continue treatment or adjust the application frequency.
The uncommon side effects listed above reflect the broader range of anticholinergic effects that can occur when glycopyrronium enters the systemic circulation. Cardiovascular effects such as rapid heart rate and QT prolongation are rare but clinically significant and should be reported to your doctor immediately. Similarly, changes in blood test results (liver enzymes, platelet count, hemoglobin) have been observed in some patients and may require monitoring.
Report any new or worsening side effects to your doctor or pharmacist, even if they are not listed above. In particular, seek medical advice if you experience difficulty urinating, significant visual disturbances, rapid or irregular heartbeat, severe constipation, or signs of overheating. If you experience side effects, your doctor may adjust the application frequency or recommend discontinuing treatment.
How Should You Store Axhidrox?
Proper storage of Axhidrox is important to ensure the medication remains effective and safe throughout its shelf life. Unlike many biological medications that require refrigeration, Axhidrox cream does not have special storage temperature requirements, making it convenient for everyday use and travel.
Follow these storage guidelines:
- Keep out of reach of children: Store Axhidrox in a safe location where children cannot access or accidentally use it. Accidental ingestion by children is a medical emergency requiring immediate attention.
- No special storage conditions: Axhidrox can be stored at normal room temperature. No refrigeration is required.
- Check the expiration date: Do not use Axhidrox after the expiration date printed on the label and carton after “EXP.” The expiration date refers to the last day of the indicated month.
- In-use shelf life: After the first pump actuation, the medication may be used for a maximum of 12 months, regardless of the printed expiration date. If 12 months have passed since you first used the pump, discard the remaining product even if it has not been fully used.
- Treatment tracking: Each 50 g container delivers 124 pump actuations, which is sufficient for 31 complete treatments (4 actuations per treatment, treating both armpits). After 31 treatments, do not continue to use the pump even if the container is not completely empty, as the remaining amount may not deliver a full dose.
- Proper disposal: Do not dispose of medicines through wastewater or household waste. Ask your pharmacist how to properly dispose of medications that are no longer needed. These measures help protect the environment.
What Does Axhidrox Contain?
Active Ingredient
The active substance is glycopyrronium (administered as glycopyrronium bromide). Each gram of cream contains glycopyrronium bromide equivalent to 8 mg of glycopyrronium. Each pump actuation delivers 270 mg of cream containing glycopyrronium bromide equivalent to 2.2 mg of glycopyrronium. Glycopyrronium bromide is a synthetic quaternary ammonium compound with potent antimuscarinic (anticholinergic) properties.
Inactive Ingredients (Excipients)
| Ingredient | Role | Notes |
|---|---|---|
| Glycopyrronium bromide | Active substance (anticholinergic) | 2.2 mg glycopyrronium per pump actuation |
| Benzyl alcohol (E1519) | Preservative | ~2.7 mg per pump; may cause allergic reactions |
| Propylene glycol (E1520) | Solvent / humectant | ~8.1 mg per pump |
| Cetostearyl alcohol | Emulsifier / thickener | May cause local skin reactions (contact dermatitis) |
| Citric acid (E330) | pH adjuster | Maintains cream stability |
| Glycerol monostearate 40–55 | Emulsifier | Stabilizes cream formulation |
| Macrogol 20 glycerol monostearate | Emulsifier | Helps blend oil and water phases |
| Sodium citrate (E331) | Buffer / pH stabilizer | Works with citric acid |
| Octyldodecanol | Emollient | Improves skin feel and spreadability |
| Purified water | Vehicle / solvent | Base of the cream formulation |
Packaging and Appearance
Axhidrox is a white, glossy cream supplied in a multi-dose container with a pump and cap. Each container holds 50 g of cream. After the pump has been primed (first-time use only), it delivers 124 pump actuations, which is sufficient for 31 complete treatments (treating both armpits). The pump cap serves as the application device — cream is dispensed onto the cap and then spread in the armpit using the cap, rather than the fingers. After 31 treatments, the pump should be discarded even if some cream appears to remain in the container, as the remaining amount may not deliver the correct dose.
Frequently Asked Questions About Axhidrox
Regular over-the-counter antiperspirants typically contain aluminum salts (such as aluminum chlorohydrate or aluminum zirconium) that work by physically blocking sweat ducts. Axhidrox works through a completely different mechanism: it contains glycopyrronium, an anticholinergic agent that blocks the nerve signals (acetylcholine) that stimulate sweat glands to produce sweat. This makes Axhidrox significantly more effective for people with severe primary axillary hyperhidrosis who do not respond adequately to conventional antiperspirants. However, because Axhidrox is a prescription medication with potential systemic effects, it is reserved for cases where regular antiperspirants have proven insufficient.
Axhidrox should always be applied using the pump cap as an applicator, never with bare fingers. This is because glycopyrronium can be absorbed through the skin of your fingers and hands, and the cream on your fingers could accidentally be transferred to your eyes, nose, or mouth, causing anticholinergic side effects at those sites. Getting the cream in your eyes could cause blurred vision and pupil dilation; in your nose or mouth, it could cause excessive dryness. Using the cap as an applicator and washing your hands immediately afterwards significantly reduces this risk.
No. Axhidrox is approved and formulated exclusively for application to the armpit area. It must not be applied to hands, feet, face, or any other body area. Applying Axhidrox to larger skin areas significantly increases systemic absorption of glycopyrronium, which raises the risk of serious anticholinergic side effects. Furthermore, reducing sweating over large body areas can impair your body's ability to regulate its temperature through evaporative cooling, potentially leading to dangerous overheating and heat stroke. If you experience excessive sweating in areas other than the armpits, discuss alternative treatment options with your dermatologist.
Most patients begin to notice a reduction in underarm sweating within the first few weeks of daily application. The full effect typically develops over the 4-week induction period, during which the cream is applied once daily. By the end of the fourth week, your doctor will assess your response to determine whether you can reduce the application frequency to twice weekly for maintenance. Some patients may experience benefit sooner, while others may need the full induction period. If you do not notice any improvement after 4 weeks of consistent daily use, consult your doctor to discuss your treatment options.
Yes. Axhidrox provides symptomatic relief from excessive underarm sweating, but it does not cure the underlying condition. Primary axillary hyperhidrosis is a chronic condition, and when you stop applying Axhidrox, the excessive sweating will gradually return as the glycopyrronium is cleared from the skin and sweat glands. The timeline for sweating to return varies between individuals but is typically within a few days to a couple of weeks after discontinuation. For long-term management, continuous treatment is generally required.
Clinical data support the use of Axhidrox over treatment periods studied in clinical trials. The safety profile appears consistent over time, with no new safety signals emerging with prolonged use. However, long-term safety data beyond the clinical trial period is still being collected through post-marketing surveillance. If you use Axhidrox long-term, your doctor should review your treatment periodically to ensure it remains appropriate and to monitor for any cumulative anticholinergic effects. Regular dental check-ups are also recommended if you experience persistent dry mouth, as reduced saliva increases the risk of dental problems over time.
References
- European Medicines Agency (EMA). Axhidrox – Summary of Product Characteristics. Last updated 2024. Available from: www.ema.europa.eu
- Nawrocki S, Cha J. The etiology, diagnosis, and management of hyperhidrosis: A comprehensive review. Part 1. Etiology and clinical work-up. Journal of the American Academy of Dermatology. 2019;81(3):657–666. doi:10.1016/j.jaad.2018.12.071
- Nawrocki S, Cha J. The etiology, diagnosis, and management of hyperhidrosis: A comprehensive review. Part 2. Therapeutic options. Journal of the American Academy of Dermatology. 2019;81(3):669–680. doi:10.1016/j.jaad.2018.11.066
- Glaser DA, Hebert AA, Pariser DM, Solish N. Facial hyperhidrosis: best practice recommendations and special considerations. Cutis. 2007;79(5 Suppl):29–32.
- Hornberger J, Grimes K, Naumann M, et al. Recognition, diagnosis, and treatment of primary focal hyperhidrosis. Journal of the American Academy of Dermatology. 2004;51(2):274–286. doi:10.1016/j.jaad.2003.12.029
- British Association of Dermatologists (BAD). Hyperhidrosis Clinical Guidelines. 2023. Available from: www.bad.org.uk
- American Academy of Dermatology (AAD). Guidelines of care for the management of primary focal hyperhidrosis. Journal of the American Academy of Dermatology. 2024.
- International Hyperhidrosis Society. Treatment Algorithm for Primary Focal Hyperhidrosis. 2023. Available from: www.sweathelp.org
- Haider A, Solish N. Focal hyperhidrosis: diagnosis and management. Canadian Medical Association Journal. 2005;172(1):69–75. doi:10.1503/cmaj.1040708
- World Health Organization (WHO). Model List of Essential Medicines. 23rd List. 2023. Available from: www.who.int
Editorial Team
Medical Content
Written by iMedic Medical Editorial Team – Specialists in Dermatology and Clinical Pharmacology
Medical Review
Reviewed by iMedic Medical Review Board according to international guidelines (EMA, BAD, AAD, IHhS)
Evidence Standard
Evidence Level 1A – Based on systematic reviews, randomized controlled trials, and international clinical guidelines
Independence
No commercial funding. No pharmaceutical company sponsorship. Independent medical editorial content following GRADE evidence framework.
Published: | Last Reviewed: